NCT Number: NCT02425436
Role of Ginkgo Biloba Extract in IUGR
The use of herbal medicinal products is increasing enormously in recent years, mainly among women, who use them for the most varied purposes, such as in menstrual problems, menopausal symptoms, mood disturbances and to strengthen their bones. Most of these benefits are due to the flavonoids present in these products. These flavonoids have anticarcinogenic, antiviral, antioxidant and antiinflammatory activities, as well as being used in the treatment of osteoporosis, menopausal symptoms and cardiovascular diseases . Besides the benefits from the consumption of flavonoids, little is known about their safety and potentially harmful toxic effects, such as mutagenicity and genotoxicity which might occur if taken in large doses . Safety of Ginkgo biloba during pregnancy or lactation was not criticized in literature. Roasted and raw ginkgo seed were not reported in the evidence-based medicine literature as being either safe or contraindicated in pregnancy or lactation. A higher incidence of postpartum hemorrhage was reported in the literature when associated with a 3-month ingestion of Ginkgo Biloba extract. Flavonoids are components of Ginkgo biloba L. (Ginkgoaceae), a medicinal plant widely used by the population . G. biloba has its origin in China, Korea and Japan where its fruits and leaves have been used as food and medicine for a long time.
The extract of G. biloba (EGb) is composed of different terpene trilactones, i.e., ginkgolides A, B, C, J and bilobalide, many flavonol glycosides, biflavones and alkylphenols . The major flavonoids in the extract are kaempferol, quercetin and isorhamnetin] whose metabolites were found in the blood of rats and in human urine after oral administration of EGb. Due to its actions as an anti-inflammatory and antioxidant, EGb has been largely used in the treatment of Alzheimer's disease, pre-menstrual syndrome, cerebrovascular insufficiency and peripheral arterial occlusive disease . In folk medicine, EGb is used as a vermifuge, to induce labor, for the treatment of bronchitis, chronic rhinitis, chilblains, arthritis and edema . The aim of this study was to evaluate the effect of oral supplementation of Ginkgo Biloba extract on the fetal weight as well as feto-maternal blood flow in cases of intrauterine growth restriction.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year–35 year
Sex eligibility
Female
Study type
Interventional
Phase
Phase 2
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Pregnant women in their third trimester (28-30 weeks of gestation).
- Pregnant women whose pregnancy was complicated with intra uterine growth restriction (IUGR).
- Normal Doppler indices in uterine, umbilical and middle cerebral arteries at time of recruitment.
Exclusion criteria
- Multiple pregnancies,
- Hypertension,
- Fetal congenital anomalies,
- Previous history of congenital anomalies or chromosomal abnormalities.
- Diabetes Mellitus
- Premature pre-labor rupture of membranes
- Antepartum hemorrhage
Treatment and study plan
Placebo
OtherPrimary outcomes
-
Fetal weight (gm)
Time frame: one and half year
Secondary outcomes
-
Doppler blood flow changes in uterine arteries indices
Time frame: one and half year
-
Doppler blood flow changes in umbilical arteries indices
Time frame: one and half year
-
Doppler blood flow changes in middle cerebral artery indices
Time frame: one and half year
Sponsors and collaborators
Lead sponsor
Assiut University
Other
Registry information
Official study title
Effects of Oral Ginkgo Biloba Extract on Pregnancy Complicated by Asymmetrically Intrauterine Growth Restriction: a Double-blinded Randomized Placebo-controlled Trial
Important dates
- Study start
- 2014
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Apr 24, 2015
- Registry last updated
- Mar 22, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Ductus Venosus Doppler in IUGR Pregnancies
NCT07193381
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
Izmir, Bayrakli, Turkey (Türkiye)
View Trial DetailsIntrauterine Growth Restriction and Intrauterine Fetal Death
NCT07031583
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Female Urogenital Diseases and Pregnancy Complications
Kayseri, Turkey (Türkiye)
View Trial DetailsPerinatal Conditions Influencing Morbidity, Mortality, and Medical Care in Newborns
NCT06653374
Abruptio Placentae, Asphyxia Neonatorum
Quito, Pichincha, Ecuador
View Trial DetailsEstimation of Fetal Weight by Measuring Abdominal Circumference, Abdominal Subcutaneous Soft Tissue Thickness, Femur Length and Mid-thigh Soft Tissue Thickness
NCT07575152
Birth Weight, Body Weight
View Trial Details